A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)

Trial Profile

A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Emicerfont (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Nov 2009 Results were presented at GASTRO 2009.
    • 15 Oct 2008 Actual start date changed from Jul 2006 to Dec 2006 as reported by Clinicaltrials.gov.
    • 12 Oct 2008 Phase changed from I/II to II as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top